Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Next Previous
Search
Trial Profile

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary) ; Clobetasol
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ReDOS

    • Most Recent Events

    • 09 Mar 2023 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2022 Results of a network analysis of data pooled from 3 global (ReDOS, CORRECT, RECOURSE) and 3 Asian (TERRA, Yoshino 2012, and CONCUR) studies assessed the impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer
    • 02 Jul 2022 Results assessing dosing strategy and clinical real-world outcomes among patients with metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top